Интенсивный контроль артериального давления: возможности комбинированной фармакотерапии

1. Davis BR, Cutler JA et al. Rationale and design for the Antihypertensive and Lipid Lowering treatment to prevent Heart Attack Trial (ALLHAT). Am J Hypertens 1996; 9: 342–60.
2. SHEP Co-operative research group prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 1991; 265: 3255–64.
3. Pepine CJ et al. INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronaryartery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290 (21): 2805–16.
4. Danhlo..f B, Gosse P. on behalf of the PICXEL investigators. Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study. J Hypertens 2005; 11: 2063–70.
5. Danhlo..f B et al. Cardiovascular morbidity and mortality in the Losartan intervention for endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995–1003.
6. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertensive Optimal Treatment (HOT) randomized trial. Lancet 1998; 351: 1755–62.
7. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and micro vascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703–13.
8. Диагностика и лечение артериальной гипертензии. Российские рекомендации (3-й пересмотр), М., 2008.
9. Беленков Ю.Н. и рабочая группа исследования ЭПИГРАФ-2: Агеев Ф.Т., Бойцов С.А., Лазебник Л.Б., Мареев В.Ю., Оганов Р.Г., Ольбинская Л.И., Обренович-Кирчански Б., Остоич М., Поздняков Ю.М., Чазова И.Е., Шляхто Е.В. Эналаприл Плюс Индапамид в лечении артериальной Гипертонии: оценка эффективности и безопасности РАциональной Фармакотерапии. Применение нефиксированной комбинации эналаприла и индапамида (Энзикс). Дизайн и основные результаты исследования ЭПИГРАФ – 2. Сердце. 2005; 4 (5): 98–103.
10. Беленков Ю.Н., Мареев В.Ю. от имени рабочей группы исследования ЭПИГРАФ. Эналаприл Плюс Индапамид в лечении стабильной артериальной Гипертонии: оценка эффективности и безопасности РАциональной комбинированной Фармакотерапии (ЭПИГРАФ). Первые результаты Российского многоцентрового исследования ЭПИГРАФ-1. Сердце. 2003; 2 (4): 3–7.
11. Мартынюк Т.В., Колос И.П., Чазова И.Е. от имени соисследователей программы СТРАТЕГИЯ. Эффективность и безопасность фиксированной комбинации малых доз периндоприла/индапамида у пациентов с артериальной гипертонией в условиях реальной практической практики. Кардиоваскул. тер. и профилак. 2007; 6 (8): 21–7.
12. Ruilope L, Zanchetti A. Targeting hypertension with valsartan: Lessons learned from the valsartan/HCTZ versus amlodipine in stage II hypertensive patients (VAST) trial J of the renin-angiotensin-aldosterone system 2006; 7: S1 [Note(s): S8–11.
13. Mogensen CE et al. Effect of a low dose Perindopril/indapamide on albuminuria in diabetes. Preterax in albuminuria regression: PREMIER. Hypertension 2003; 41: 1063–71.
14. PROGRESS collaborative group. Randomised trial of perindopril-based blood pressure lowering regimen among 6105 individuals with previous stroke or transient ischemic attack. Lancet 2001; 358: 1033–41.
15. Mourad JJ et al. What rates of blood pressure normalisation can be expected from a first-line combination therapy in the real life? The OPTIMAX study. Eur Heart J 2006; 27(suppl.): 298. (Abstr 1792).
16. De Luca N et al. Regression of left ventricular mass in hypertensive patients treated with perindopril/indapamide as a first-line combination: the REASON echocardiography study. Am J Hypertens 2004; 8: 660–7.
17. Danhlo..f B et al. for the ASCOT investigators/Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumetiazide as required, in the anglo-Scandinavian cardiac outcomes trial blood pressure lowering arm: a multicentre randomized controlled trial. Lancet 2005; 366: 895–906.
18. Mourad JJ et al. on behalf of the investigators of the STRATHE trial. Comparision of different therapeutic strategies in hypertension: a low-dose combination of low-dose combination of perindopril/indapamide versus a sequential monotherapy or a stepped care approach. J Hypertens 2004; 22: 2379–96.
19. Advance Collaborative group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomesin patients with type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. Lancet 2007; 370: 829–40.
20. Kjeldsen SE et al. Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH study. Blood Press 2008; 17 (1): 7–17.
21. Scholze J et al. Optimal treatment of obesity-related hypertension: The hypertension-obesity-sibutramine (HOS) study. Circulation 2007; 115 (15): 1991–8.
22. Ruggenenti P et al. Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351: 1941–51.
23. Lindholm LH et al. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 2003; 21 (8): 1563–74.
24. Mogensen CE et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Brit Med J 2000; 321: 1440–4.
25. Dogrell SA. ACE inhibitors and AT-1-receptor antagonists COOPERATE in non-diabetic renal disease. Lancet 2003; 361: 117–24.
26. Joshi SR et al. Evaluation of efficacy and tolerability of Losartan and Ramipril combination in the management of hypertensive patients with associated diabetes mellitus in India (LORD Trial). J Assoc Physicians India 2004; 52: 189–95.
27. Yusuf S et al. for the ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547–59.
28. Frishman WN et al. A multifactorial trial desigh to assess combination therapy in hypertension. Treatment with bisoprolol and hydrochlorothiazide. Arch Intern Med 1994; 154: 1461–8.

Т.Б.Андрущишина, Т.Е.Морозова

ГОУ ВПО Московская медицинская академия им. И.М.Сеченова

________________________________________________

T.B. Andrushchishina, I.E. Morosova

Moscow Medical Academy of I.M. Sechenov